Our Team

David Zapol
David Zapol

Founder and CEO

David Zapol leads Third Pole, building the management team and developing partnership strategies to enable significant growth. David previously led operations of Goodlife, the largest pharmacy chain in East Africa, which he also co-founded. David was a head of the Global Health strategy consulting practice at FSG, a mission-driven consulting firm where he led teams working with clients including Pfizer, Merck, Eli Lilly and The Bill and Melinda Gates Foundation. David holds an MBA/MPH from Columbia and a Masters in Immunology from Stanford.

Philip Silkoff
Philip E Silkoff, M.D.

Chief Medical Officer

Philip E. Silkoff is an experienced senior pharmaceutical physician who leads our clinical and regulatory efforts. Phil previously held the positions of Senior Medical Director at Janssen R&D and Medical Director at AstraZeneca. Phil has overseen multiple clinical studies in asthma, COPD, interstitial pulmonary fibrosis and sarcoidosis. Prior to industry, Phil was Associate Professor at National Jewish Health in Denver, Colorado. Phil is a renowned expert in exhaled nitric oxide measurement and holds several patents in the field. Dr. Silkoff holds an MBBS in Respiratory Medicine from University College London and an MBBS in Medicine from the University of London.

Greg Hall
Greg Hall, Ph.D

Vice President, Product Development

Greg Hall is Third Pole’s technical leader and lead engineer, building on 18 years experience in the medical device industry. Prior to joining Third Pole, Greg served as General Manager at Cirtec Medical and has been VP of Engineering for several medical device development endeavors. Greg has led development programs for software-controlled electromechanical systems through clinical evaluation and regulatory approval and is an inventor on more than 12 issued patents. His formal education includes a Ph.D. from the University of Virginia, a Masters degree from Clemson University in Bioengineering and a BS degree in mechanical engineering from Rose-Hulman Institute of Technology.

Wolfgang Scholz
Wolfgang Scholz

Head of Product Marketing

Wolfgang has 40 years of executive management experience with leading global companies in the medical device industry, including bringing four generations of patient monitoring systems to the market. Wolfgang brings a unique expertise and detailed knowledge of all aspects in the definition, the creation, the manufacturing, the regularly requirement of CE /FDA and servicing a medical product / system in the international market. His background includes analysis of medical markets and international healthcare systems, strategic marketing, development, and assessment of business plans for health technology products, appraisal and evaluation of new medical technologies, clinical evidence, medical workflow and process analysis and control, and FDA, CE and ISO compliance.

David Fogel
David A. Fogel, CPA

Chief Financial Officer

David’s expertise lies in constructing a reliable financial framework to attract funding. He possesses over 26 years of senior financial management experience in various capacities for a variety of high technology related companies, including GSI Lumonics, Lilliputian Systems, RNK Communications, and Core-M, Inc. Most recently Mr. Fogel was the CFO of the healthcare IT consulting firm Beacon Partners, and previously was Vice President of Finance and Treasurer at Webgen Systems, Inc., a provider of advanced solutions for building energy management, controls and conservation. David is a licensed Certified Public Accountant (CPA). David has a BS from Miami University (Ohio), and a MBA from the University of Cincinnati.

Elizabeth A. Holmberg
Elizabeth A. Holmberg

Vice President, Finance and Corporate Development 

Elizabeth A. Holmberg oversees the planning and execution of strategies to meet financial and organizational objectives for Third Pole. Previously, Elizabeth served as Vice President of Finance at MannKind Corporation, a biopharmaceutical company whose lead product, Afrezza®, an inhaled prandial insulin, was approved in 2014, where she was responsible for financial operations and strategic partnering. Prior to MannKind, Elizabeth was the Chief Financial Officer for Ikaria after spending many years in finance and strategic planning roles of increasing responsibility with Ohmeda, Becton Dickinson and INO Therapeutics. INO Therapeutics was the first company to gain FDA approval for inhaled nitric oxide therapy, prior to being acquired by Ikaria. Elizabeth joined INO Therapeutics prior to the approval of INOmax® and had direct responsibility for the accounting, finance and planning functions for the company through their transition from a clinical start-up to a fully integrated, commercial pharmaceutical company. Elizabeth received an MBA from New York University’s Leonard N. Stern School of Business and a Bachelor of Science in Accounting from The William Paterson University of New Jersey.

In This Section